SIGIRR/TIR8, an important regulator of TLR4 and IL-1R-mediated NF-κB activation, predicts biochemical recurrence after prostatectomy in low-grade prostate carcinomas

Human Pathology
Tyler M BaumanWilliam A Ricke

Abstract

Single Ig IL-1-related receptor (SIGIRR) is a negative regulator of toll-like receptor 4 and IL-1-mediated activation of nuclear factor κ-light-chain enhancer of activated B cells. The purpose of this study was to qualitatively and quantitatively determine SIGIRR protein expression in human prostate tissues and associate SIGIRR expression with clinical parameters. SIGIRR expression was quantified in glandular prostate tissue using immunohistochemistry and multispectral imaging, and expression was evaluated in relation to clinicopathological features of benign prostatic hyperplasia and prostate cancer (PCa). Subgroupings of low Gleason score (≤ 6 and 3 + 4) and high Gleason score (4 + 3 and ≥ 8) were used for patient outcomes. SIGIRR was predominantly expressed in the cytoplasm and nucleus of the prostatic epithelium with little expression within the stroma. Compared with normal prostate, cytoplasmic SIGIRR expression was similar in benign prostatic hyperplasia, high-grade prostatic intraepithelial neoplasia, PCa, and metastases. A decrease in nuclear expression was found in metastasis samples (P = .04). Changes in SIGIRR expression were not associated with Gleason score, pathological stage, tumor volume, surgical margin status,...Continue Reading

References

Feb 28, 2003·Science's STKE : Signal Transduction Knowledge Environment·Aisling Dunne, Luke A J O'Neill
Aug 28, 2003·Nature Immunology·Luke A J O'Neill
Mar 30, 2004·Clinical Prostate Cancer·Catherine M TangenMaha Hussain
Jan 13, 2006·The Journal of Urology·John S LamArie S Belldegrun
Mar 27, 2007·Nature Reviews. Cancer·Angelo M De MarzoWilliam G Nelson
Jun 9, 2007·The Journal of Clinical Investigation·Carlos Cordon-CardoMichael J Donovan
Feb 25, 2010·Annals of Surgical Oncology·Stephen B Edge, Carolyn C Compton
Jul 21, 2011·Nature Immunology·Yinon Ben-Neriah, Michael Karin
Jan 4, 2012·Histopathology·Karen S Sfanos, Angelo M De Marzo
Jul 18, 2012·Annals of Internal Medicine·Virginia A Moyer, UNKNOWN U.S. Preventive Services Task Force
Oct 4, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H Ballentine CarterJonathan I Epstein
Jun 25, 2013·Differentiation; Research in Biological Diversity·Tristan M NicholsonWilliam A Ricke
Dec 18, 2013·Immunity·Cecilia GarlandaAlberto Mantovani
Jan 7, 2015·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal

❮ Previous
Next ❯

Citations

Dec 13, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Scott E EggenerHimisha Beltran
Oct 31, 2020·Journal of Immunology Research·Feng TianTao Jiang
Aug 6, 2018·Medical Hypotheses·Michael A LissZelton Dave Sharp

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.